Zentalis Pharmaceuticals IncZNTL
Price$2.77

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0-100.0% YoYTTM through 30 Jun 2026
Net Income -$137.1MTTM through 30 Jun 2026
Free Cash Flow -$128.1MTTM through 30 Jun 2026

Margins

Current

Returns

-53.6%ROE
-49.1%ROA

Balance Sheet Health

Debt / Equity0.21x
Current Ratio6.19x
Net Debt-$177.1Mnet cash position
Cash & Equivalents$24.8M

Quality Metrics

Altman Z-Score-7.35
Piotroski F-Score2 / 9
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'22'23'24'25
FY2025: $0
Diluted EPS-$1.96TTM
'19'20'21'22'23'24'25
FY2025: $-1.91

Dividend

No dividend

Capital Allocation

R&D Spend$116.3M

Segment Performance

SegmentRevenueYoYOutlook
Azenosertib Development$0
View details

DENALI Phase 2 trial topline readout expected by year-end 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.